pirfenidone has been researched along with rifampin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ahidjo, BA; Andrade, BB; Beck, S; Bishai, WR; Cheung, LS; Ihms, EA; Jain, S; Maiga, M; Maiga, MC; Ordonez, AA | 1 |
2 other study(ies) available for pirfenidone and rifampin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Isoniazid; Mice; Mice, Inbred C3H; Pyrazinamide; Pyridones; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |